Are These Truly Rheumatoid Arthritis or Antisynthetase Syndrome Cases?

References (11)

1. Matsushita M, Tamura N, Ogasawara M, Tada K, Yamaji K, Takasaki Y. The Association of Anti- Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease. Arch Rheumatol 2018;33:26-32
2. Kennish L, Labitigan M, Budoff S, Filopoulos MT, McCracken WA, Swearingen CJ, et al. Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care. BMJ Open 2012;2(5). pii: e001117
3. Britsemmer K, Ursum J, Gerritsen M, van Tuyl LH, van Schaardenburg D. Validation of the 2010 ACR/ EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis 2011;70:1468-70
4. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011;13:175-81
5. Patel HC, Lauder NN. The antisynthetase syndrome. Am J Med 2011;124:e3-4
6. Tzioufas AG. Antisynthetase syndrome. Orphanet Encyclopedia 2001:1-5
7. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37:100-9
8. Mumm GE, McKown KM, Bell CL. Antisynthetase syndrome presenting as rheumatoid-like polyarthritis. J Clin Rheumatol 2010;16:307-12
9. Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med 2016;118:39-45
10. Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studynková J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis 2018;77:55-62
11. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.